Bristol-Myers Squibb and ONO Pharmaceutical’s New Study on Nivolumab for NSCLC: What Investors Need to Know

Bristol-Myers Squibb Company ((BMY)), ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.

In a recent update, Bristol-Myers Squibb and ONO Pharmaceutical Co. announced a new clinical study titled ‘A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan.’ The study aims to evaluate the effectiveness and safety of Nivolumab combined with chemotherapy for patients with non-small cell lung cancer (NSCLC), focusing on pathologic complete response (pCR) and progression-free survival (PFS).

The intervention being tested is Nivolumab, an immunotherapy drug, used in combination with chemotherapy. This combination is intended to improve treatment outcomes for NSCLC patients by enhancing the body’s immune response against cancer cells.

The study is designed as a retrospective observational cohort study, meaning it will look back at existing data from patients who have already received the treatment as part of their standard care. The primary purpose is to gather real-world evidence on the treatment’s effectiveness and safety.

The study is not yet recruiting, with the initial submission date on August 28, 2025, and the last update on September 9, 2025. These dates are crucial as they mark the beginning of the study’s timeline and its most recent updates, indicating the study’s current status and progress.

For investors, this study could impact the stock performance of Bristol-Myers Squibb and ONO Pharmaceutical by potentially validating the effectiveness of Nivolumab in a new therapeutic setting. Positive results could enhance investor sentiment and strengthen the companies’ positions in the competitive oncology market.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.